Using a point-of-dispensing clinic for prophylaxis of meningococcal disease.
A point-of-dispensing clinic was held to distribute ciprofloxacin prophylaxis when 2 high school students were reported to the health department with invasive meningococcal disease. Of more than 3,100 school staff and students in attendance, 2,861 received prophylaxis. A survey was administered to students 2 weeks postclinic to better understand the motivations for clinic attendance and to quantify side effects of oral 500-mg ciprofloxacin prophylaxis. Data collected included reasons for attendance and perception of risk for acquiring meningococcal disease, rated on a 1-to-5 scale; type of contact with cases; and side effects. Of 2,888 students, 1,624 completed surveys; 1,390 took ciprofloxacin. The students rated parental influence and directives from the high school as reasons for attendance a mean of 3.97 and 3.34, respectively. The mean rating for risk of acquiring meningococcal disease was 1.49. Only 3% reported direct contact with case(s). Side effects, most commonly headache (17%) and stomachache (10%), were reported in 40% of students. Serious side effects such as rash and facial swelling were reported in <1%. In this adolescent population, few serious side effects and no joint disorders were reported after they ingested single-dose ciprofloxacin; however, many received the prophylaxis unnecessarily. Students were motivated by parents and school officials. Health departments should collaborate with schools to prepare and disseminate messages that balance the risks of unnecessary antibiotic use with those of exposure to disease.
Acute Communicable Disease Control, Los Angeles County Department of Public Health, 313 North Figueroa, Room 212, Los Angeles, CA 90012, USA. vngo@ph.lacounty.gov
Van P
VP
Ngo
Rachel H
RH
Civen
David E
DE
Dassey
Deborah
D
Davenport
Laurene
L
Mascola
D000293:Adolescent; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects; D019072:Antibiotic Prophylaxis / Q000009:adverse effects*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D019538:Health Care Surveys; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000188:drug therapy* / Q000517:prevention & control*; D009345:Neisseria meningitidis / Q000187:drug effects; D004364:Pharmaceutical Preparations / Q000600:supply & distribution*; D019095:Point-of-Care Systems / Q000458:organization & administration*; D019564:Unnecessary Procedures
D000890:Anti-Infective Agents; D004364:Pharmaceutical Preparations; D002939:Ciprofloxacin